PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV.  Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions.

On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY.  She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care.  Alex currently provides clinical leadership for HIV treatment and prevention programs. 

Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content: 

• PrEP to Prevent HIV and Promote Sexual Health
• University of Liverpool HIV Drug Interactions Checker (website and app)
• CEI Line: 1-866-637-2342
• https://ceitraining.org/